Skip header and navigation

Refine By

   MORE

8 records – page 1 of 1.

[Effect of 3-phenyl-thiazolidine-dion-2,4-derivatives on some mycobacteria]

https://arctichealth.org/en/permalink/ahliterature70100
Source
Mikrobiol Zh. 1970 May-Jun;32(4):518-20
Publication Type
Article

[Immunological studies in the treatment of tuberculosis with flureniside]

https://arctichealth.org/en/permalink/ahliterature69513
Source
Probl Tuberk. 1997;(5):27-8
Publication Type
Article
Date
1997
Author
R I Sibirnaia
Author Affiliation
NII of Epidemiology and Hygiene, Ukraine Department of Health, L'vov.
Source
Probl Tuberk. 1997;(5):27-8
Date
1997
Language
Russian
Publication Type
Article
Keywords
Antibodies, Bacterial - immunology
Antitubercular Agents - therapeutic use
Comparative Study
English Abstract
Follow-Up Studies
Heterocyclic Compounds - therapeutic use
Humans
Immunity, Cellular - drug effects
Mycobacterium tuberculosis - drug effects - immunology - isolation & purification
T-Lymphocytes - drug effects - immunology
Treatment Outcome
Tuberculosis, Pulmonary - drug therapy - immunology - microbiology
Abstract
The studies have concluded that flureniside therapy has a positive impact on immunological responsiveness in new cases of pulmonary tuberculosis. Positive immunological changes are followed by cessation of bacterial isolation. The findings suggest that it is expedient to use flureniside in the complex therapy of pulmonary tuberculosis.
PubMed ID
9454246 View in PubMed
Less detail

[Multiresistant tuberculosis in Denmark 1993-1996]

https://arctichealth.org/en/permalink/ahliterature33865
Source
Ugeskr Laeger. 1998 May 18;160(21):3066-9
Publication Type
Article
Date
May-18-1998
Author
K. Viskum
A. Kok-Jensen
Author Affiliation
Lungemedicinsk klinik, Rigshospitalet, København.
Source
Ugeskr Laeger. 1998 May 18;160(21):3066-9
Date
May-18-1998
Language
Danish
Publication Type
Article
Keywords
Adult
Antitubercular Agents - therapeutic use
Child, Preschool
Denmark - ethnology
Drug Resistance, Microbial
Drug Resistance, Multiple
Emigration and Immigration
English Abstract
Female
Humans
Male
Middle Aged
Mycobacterium tuberculosis - drug effects - immunology
Travel
Tuberculosis, Pulmonary - drug therapy - immunology - transmission
Abstract
Infections with multiresistant tubercle bacilli have also become a problem in the rich part of the world. The reasons are lack of compliance in patients with life style problems and ineffectiveness of the health system due to lack of fundings. During a four year period, 1993-1996 ten patients were seen in Denmark with tuberculosis due to multiresistant Mycobacterium tuberculosis. Nine were infected abroad, one developed MDR-TB during treatment in Denmark. It is possible to cure these patients, but it is expensive and takes a long time. In the future more cases created within Denmark are likely to be seen due to lack of funding for the tuberculosis programme and, depending on immigration, further cases created abroad are expected.
PubMed ID
9621779 View in PubMed
Less detail

[The global tuberculosis problem. An apparition from history?]

https://arctichealth.org/en/permalink/ahliterature8002
Source
Tidsskr Nor Laegeforen. 1994 Feb 20;114(5):578-81
Publication Type
Article
Date
Feb-20-1994
Author
G. Bjune
E. Heldal
Author Affiliation
Avdeling for vaksine, Statens Institutt for Folkehelse, Oslo.
Source
Tidsskr Nor Laegeforen. 1994 Feb 20;114(5):578-81
Date
Feb-20-1994
Language
Norwegian
Publication Type
Article
Keywords
Africa - epidemiology
Americas - epidemiology
Developing Countries - statistics & numerical data
Disease Outbreaks - history
Drug Resistance, Microbial
English Abstract
Europe - epidemiology
HIV Infections - complications - epidemiology - transmission
History, 20th Century
Humans
Mycobacterium tuberculosis - drug effects - immunology
Tuberculosis - epidemiology - history - transmission
World Health
Abstract
Tuberculosis is increasing, partly because of concomitant HIV-infection, but with poverty and lack of social welfare and public health services contributing substantially. Current treatment for tuberculosis has proved efficacious also in HIV-infected patients, and so far seems to have prevented increased transmission of the disease in Tanzania. Strictly controlled chemotherapy provides the only hope of preventing the emergence of multi-resistant tubercle bacilli. The World Bank has evaluated tuberculosis control as the most cost-effective form of health intervention among adults. Norway has made a substantial contribution to the development of a model for tuberculosis control in developing countries and to international mycobacterial research; and therefore has a special responsibility to meet the new challenge.
PubMed ID
7516095 View in PubMed
Less detail

[Tuberculosis a threat again. Multiresistance in the Baltic States and in Russia; Nordic countries initiate cooperation to prevent transmission]

https://arctichealth.org/en/permalink/ahliterature69428
Source
Lakartidningen. 2000 Nov 29;97(48):5606-10
Publication Type
Article
Date
Nov-29-2000
Author
A. Rutqvist
G. Boman
K. Ekdahl
S. Hoffner
I. Julander
L O Larsson
M. Ridell
Author Affiliation
Göteborgs universitet. tb-meeting@medfak.gu.se
Source
Lakartidningen. 2000 Nov 29;97(48):5606-10
Date
Nov-29-2000
Language
Swedish
Publication Type
Article
Keywords
Antitubercular Agents - administration & dosage - adverse effects
Baltic States - epidemiology
Communicable disease control
Communicable Diseases, Emerging - prevention & control - transmission
Disease Outbreaks
Drug Resistance, Multiple
English Abstract
Humans
Incidence
International Cooperation
Mycobacterium tuberculosis - drug effects - immunology
Practice Guidelines
Russia - epidemiology
Scandinavia
Tuberculosis, Multidrug-Resistant - drug therapy - epidemiology - prevention & control - transmission
Tuberculosis, Pulmonary - epidemiology - prevention & control - radiography - transmission
Abstract
The incidence of tuberculosis (TB) has more than doubled in the Baltic States during the last decade and is now 10-15 times higher than in Sweden. It is also a serious problem in Russia. Strains resistant to one or several of the anti-tuberculous drugs are common as is multi-drug resistance (MDR), i.e. strains resistant to the two most effective drugs rifampicin and isoniazid. MDR-TB is very difficult to treat; the mortality rate is high. Initiatives have been taken in the Nordic countries in order to help to control and improve the situation by way of supportive measures.
PubMed ID
11187376 View in PubMed
Less detail

[Tuberculosis--still a challenge. Can we prevent development of resistance of killer bacteria?]

https://arctichealth.org/en/permalink/ahliterature69606
Source
Ugeskr Laeger. 1993 Jun 21;155(25):1974-5
Publication Type
Article
Date
Jun-21-1993
Author
E. Borg
A. Kok-Jensen
A. Vestergaard
K. Viskum
Author Affiliation
Bispebjerg Hospital, lungemedicinsk afdeling P.
Source
Ugeskr Laeger. 1993 Jun 21;155(25):1974-5
Date
Jun-21-1993
Language
Danish
Publication Type
Article
Keywords
Denmark
Drug Resistance, Microbial
Humans
Mycobacterium tuberculosis - drug effects - immunology
Tuberculosis, Pulmonary - drug therapy - immunology - microbiology
PubMed ID
8317066 View in PubMed
Less detail

[When can tuberculosis be eradicated in Denmark?]

https://arctichealth.org/en/permalink/ahliterature7906
Source
Ugeskr Laeger. 1995 Jan 16;157(3):273-9
Publication Type
Article
Date
Jan-16-1995
Author
A. Kok-Jensen
Author Affiliation
Lungeklinikken/afdeling P., Bispebjerg Hospital, København.
Source
Ugeskr Laeger. 1995 Jan 16;157(3):273-9
Date
Jan-16-1995
Language
Danish
Publication Type
Article
Keywords
Denmark - epidemiology
Drug Resistance, Microbial
Emigration and Immigration
English Abstract
Humans
Mycobacterium tuberculosis - drug effects - immunology
Prevalence
Tuberculosis - epidemiology - prevention & control - transmission
Abstract
Eradication is here defined as a tuberculosis (tbc.) incidence below one case of contagious tbc. per million per year and a Mycobacterium tuberculosis (Mt) infection prevalence of 1% or lower and declining. The situation is evaluated separately for Danes and foreigners. Late cases of tbc due to Mt infection more than five years earlier will decline with declining Mt infection prevalence over 50 years. Early tbc. due to Mt infection within five years can with good case finding, effective treatment, and contact examination be kept at a level of 33% of late cases. Relapses are now 15% of all cases and will also decline relatively. HIV/tbc. will only be a limited problem for a few years due to a low Mt infection prevalence. Continued limited immigration will only have minor influence on tbc. among Danes. Tbc. in immigrants already living in Denmark will decline over 10-20 years to around 20/100,000 but can not be eradicated in first generation immigrants. MT resistance will not be of importance for eradication. It is estimated that only major social disasters will be able to prevent eradication of tbc. among Danes by 2040.
PubMed ID
7846773 View in PubMed
Less detail

[When will the new tuberculosis vaccine appear?].

https://arctichealth.org/en/permalink/ahliterature265387
Source
Zh Mikrobiol Epidemiol Immunobiol. 2015 Jan-Feb;(1):86-94
Publication Type
Article
Author
A M Koroliuk
L A Zazimko
S V Petrovskii
Source
Zh Mikrobiol Epidemiol Immunobiol. 2015 Jan-Feb;(1):86-94
Language
Russian
Publication Type
Article
Keywords
BCG Vaccine - adverse effects - therapeutic use
Humans
Mycobacterium bovis - drug effects - immunology - pathogenicity
Mycobacterium tuberculosis - drug effects - immunology - pathogenicity
Russia
Tuberculosis - epidemiology - genetics - immunology - prevention & control
Tuberculosis Vaccines - genetics - immunology - therapeutic use
Vaccines, Attenuated - genetics - immunology - therapeutic use
Vaccines, Synthetic - genetics - immunology - therapeutic use
Abstract
The problem of tuberculosis prophylaxis remains actual for many countries of the world including Russia. The search of candidates for substitution of the only authorized BCG vaccine has been ongoing for some time, because it does not prevent reactivation of the causative agent in the latent stage and causes generalized BCG-infection in individuals with pronounced immune deficiency. In October 2013 in Lille at the European Congress "World Vaccine 2013" results of multi-year projects and trials of around 40 novel tuberculosis vaccine candidates were presented. The article contains a critical analysis of the materials presented at the congress. 12 vaccines have been developed or are being developed for priming. Among those a live VPM 1002 vaccine based on a genetically modified BCG Mycobacterium bovis (HLY+rBCG) strain and an attenuated vaccine based on Mycobacterium tuberculosis (att. MTB-MTBVAC) have passed phase II clinical trials. 17 candidates are being examined as booster vaccines, among those 6 vaccines have passed phase II clinical trials, and are presented by both modified M. bovis strains and partial proteins of M. tuberculosis. Characteristics of the 3 most perspective vaccines have been presented at the congress: VPM 1002, H &H56 and MVA85A. VPM 1002 is the vaccine closest to introduction. This is a live recombinant anti-tuberculosis vaccine based on the BCG strain, its DNA had genes partially deleted, that code synthesis of listeriolysin. The trials have shown that protective effectiveness of the vaccine is significantly higher than the parent BCG due to better induction of CD4+ and CD8+ cells, as well as IFN-?, IL-18, 12 and other cytokines responsible for cell immunity function against M. tuberculosis.
PubMed ID
25842959 View in PubMed
Less detail

8 records – page 1 of 1.